SlideShare a Scribd company logo
1 of 15
Overview of Biological Products
FDA Basics Webinar
June 17, 2013
Mantej (Nimi) Chhina, M.S., Ph.D.
Health Science Policy Analyst
Office of Medical Policy
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Objectives
• Biological products definition
• What is a “biological product”?
• Sources for biological products
• Types of biological products
• How are biological products different?
• Questions from consumers and patients
2
Definition of Biological Product
Section 351, Public Health Service (PHS) Act
– (1) The term “biological product” means a virus,
therapeutic serum, toxin, antitoxin, vaccine, blood, blood
component or derivative, allergenic product, protein
(except any chemically synthesized polypeptide), or
analogous product, or arsphenamine or derivative of
arsphenamine (or any other trivalent organic arsenic
compound), applicable to the prevention, treatment, or
cure of a disease or condition of human beings.
42 U.S.C. § 262(i)
3
Examples of Biological Products
• Biological products are used for a wide range of diseases and
conditions, including serious and life-threatening conditions
such as cancers and rheumatoid arthritis. Some examples of
biological products and examples of their approved uses
include:
Botox: has both dermatologic and neurologic uses
Herceptin: for a certain type of breast cancer
Vaccines, for example: the Shingles vaccine and the flu
vaccines
Enbrel: for rheumatoid arthritis and psoriasis
4
What is a Biological Product?
5
• Biological products, or biologics, are medical products.
• Biological products could be made of sugars, proteins, or nucleic acids
or complex combinations of these substances, or may be living entities
such as cells and tissues.
• Like drugs, biological products are used to either:
 treat or cure diseases and medical conditions,
 prevent diseases, or
 diagnose diseases
• Biological products are made from a variety of natural sources.
Source Materials
6
Mice
Humans
Bacteria
Insect cell-culture
Transgenics
Yeast
Mammalian cell-culture
Plant cell-culture
Avian
cell-culture
Types of Biological Products
Blood Derivatives
Proteins
Whole Blood
Human Tissues Xenotransplantation
Products
Vaccines (preventive
and therapeutic)
Allergenic
ExtractsBlood
Components
Cellular &
Gene
Therapies
7
How are Biological Products Different?
8
Small Molecule Drugs Biological Products
Generally low molecular weight Generally high molecular weight
Usually organic or chemical
synthesis
Made with/from live cells/organisms
 inherent & contamination risk
Fewer critical process steps Many critical process steps
Well-characterized Less easily characterized
Known structure Structure may or may not be
completely defined or known
Homogeneous drug substance Heterogeneous mixtures
 May include variants
Usually not immunogenic Often Immunogenic
Aspirin 180 Da
Monoclonal Antibody ~150,000 Da 9
Size and Complexity of Proteins
Example of a Biotechnology Process
Harvest
Protein
mixture
Concentration
Formulation
Filling
Fermentor
Columns Purify Protein
Live
cells Biological Drug Substance
Biological Drug Product
10
Examples of Challenges for
Biological Products
• Must be processed under tightly controlled
conditions/controls throughout production to
– consistently produce a safe, pure, and potent product, and
– preclude the introduction of environmental contamination
• Biological products may be susceptible to extreme
temperatures and light
• typically need refrigeration but may need frozen storage or
preservatives
• shelf life may be limited
11
Bringing a biological product to the US market
• A manufacturer who seeks to market a biological product must
submit a biologics license application (BLA), which includes:
– Manufacturing information to demonstrate the company can properly and
consistently manufacture the biological product
– Data and information regarding the biological product (e.g., studies in animals
and humans)
– The company’s proposed labeling for the biological product. The labeling
provides necessary information about the biological product, including uses for
which it has been shown to be effective, possible risks, and how to use it.
• The biological product is licensed and can be marketed in the United
States only if
– FDA determines that the data shows the biological product is safe and effective
for its proposed use, and
– the biological product can be manufactured in a way that ensures a quality
product. 12
Summary
• Biological Products: diverse, complex products for the
treatment, diagnosis and prevention of a broad range of
common and rare diseases
• Complex processes for manufacturing, product testing, and
for evaluation of safety and efficacy
• In contrast to most drugs that are chemically synthesized and
have a known structure, most biological products are
complex mixtures that are not as easily identified or
characterized.
• Healthcare professionals and consumers can be assured that
FDA will require licensed biological products to meet the
Agency’s exacting standards of safety and effectiveness.
13
Thank you!
Questions?
14
Remember to tune in for webinar on:
Biosimilar Biological Products
Monday, August 19, 2013
1:00 PM U.S. Eastern Time Zone
15

More Related Content

What's hot

What's hot (20)

Biosimilars and generics
Biosimilars and genericsBiosimilars and generics
Biosimilars and generics
 
Biosimilar Drugs
Biosimilar DrugsBiosimilar Drugs
Biosimilar Drugs
 
European medicines agency
European medicines agencyEuropean medicines agency
European medicines agency
 
ba be studies
ba be studiesba be studies
ba be studies
 
PROCESS OF ICH (International Council for Harmonisation)
PROCESS OF ICH (International Council for Harmonisation)PROCESS OF ICH (International Council for Harmonisation)
PROCESS OF ICH (International Council for Harmonisation)
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)
 
Regulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics inRegulatory guidelines for the development of biologics in
Regulatory guidelines for the development of biologics in
 
Regulatory requirement for approval of Biologics
Regulatory requirement for approval of BiologicsRegulatory requirement for approval of Biologics
Regulatory requirement for approval of Biologics
 
Investigational New drug application [INDA]
Investigational New drug application [INDA]Investigational New drug application [INDA]
Investigational New drug application [INDA]
 
BIOLOGICALS VS BIOSIMILARS
BIOLOGICALS VS BIOSIMILARSBIOLOGICALS VS BIOSIMILARS
BIOLOGICALS VS BIOSIMILARS
 
FDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & ApprovalFDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & Approval
 
DMF -Drug Master File
DMF -Drug Master File DMF -Drug Master File
DMF -Drug Master File
 
Generic drug ppt
Generic drug pptGeneric drug ppt
Generic drug ppt
 
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...
 
ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.ICH: Introduction, objectives & guidelines: A brief insight.
ICH: Introduction, objectives & guidelines: A brief insight.
 
Drug regulation
Drug regulationDrug regulation
Drug regulation
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
 
Regulatory requirements of BIOAVAILABLITY & BIOEQUIVALENCE STUDIES
Regulatory requirements of BIOAVAILABLITY & BIOEQUIVALENCE STUDIES Regulatory requirements of BIOAVAILABLITY & BIOEQUIVALENCE STUDIES
Regulatory requirements of BIOAVAILABLITY & BIOEQUIVALENCE STUDIES
 
Combination product
Combination productCombination product
Combination product
 

Similar to FDA Presentation on Biologics

different biological product and difference between biosimilllar and generic
different biological product and difference between biosimilllar and genericdifferent biological product and difference between biosimilllar and generic
different biological product and difference between biosimilllar and generic
Charmi13
 
What is biologic, biosimilar, and biobetter
What is biologic, biosimilar, and biobetterWhat is biologic, biosimilar, and biobetter
What is biologic, biosimilar, and biobetter
Naveen Kumar Singh, Ph.D.
 
Pegylation & biosimilars global scenario
Pegylation & biosimilars   global scenarioPegylation & biosimilars   global scenario
Pegylation & biosimilars global scenario
Malay Singh
 
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
Prof. Dr. Basavaraj Nanjwade
 

Similar to FDA Presentation on Biologics (20)

different biological product and difference between biosimilllar and generic
different biological product and difference between biosimilllar and genericdifferent biological product and difference between biosimilllar and generic
different biological product and difference between biosimilllar and generic
 
USFDA NDA Vs BLA
USFDA NDA Vs BLAUSFDA NDA Vs BLA
USFDA NDA Vs BLA
 
Regulatory Requirement for the Product Approval of Biologics Ppt.pptx
Regulatory Requirement for the Product Approval of Biologics Ppt.pptxRegulatory Requirement for the Product Approval of Biologics Ppt.pptx
Regulatory Requirement for the Product Approval of Biologics Ppt.pptx
 
What is biologic, biosimilar, and biobetter
What is biologic, biosimilar, and biobetterWhat is biologic, biosimilar, and biobetter
What is biologic, biosimilar, and biobetter
 
concept of biosimilars
concept of biosimilarsconcept of biosimilars
concept of biosimilars
 
Pegylation & biosimilars global scenario
Pegylation & biosimilars   global scenarioPegylation & biosimilars   global scenario
Pegylation & biosimilars global scenario
 
Biosimilars
BiosimilarsBiosimilars
Biosimilars
 
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
 
Ethical Consideration in Bioequivalence studies.pptx
Ethical Consideration in Bioequivalence studies.pptxEthical Consideration in Bioequivalence studies.pptx
Ethical Consideration in Bioequivalence studies.pptx
 
DDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.pptDDS DRUGS AND DOSAGE FORMS-2020.ppt
DDS DRUGS AND DOSAGE FORMS-2020.ppt
 
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological ProductsFDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
 
Labelling of irradiated food and organic food
Labelling of irradiated food and organic foodLabelling of irradiated food and organic food
Labelling of irradiated food and organic food
 
Regulatory requirements for the product
Regulatory requirements for the productRegulatory requirements for the product
Regulatory requirements for the product
 
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
Regulatory Guidelines For Preclinical And Clinical Validation of Traditional ...
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
 
Overview of Laws Regulating Antibiotics in Livestock & Policy Positions of St...
Overview of Laws Regulating Antibiotics in Livestock & Policy Positions of St...Overview of Laws Regulating Antibiotics in Livestock & Policy Positions of St...
Overview of Laws Regulating Antibiotics in Livestock & Policy Positions of St...
 
Reg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.pptReg.IssuesCRO.tripati.ppt
Reg.IssuesCRO.tripati.ppt
 
biotechnology regulations.ppt
biotechnology regulations.pptbiotechnology regulations.ppt
biotechnology regulations.ppt
 
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
Drug Types: Biosimilars, generics and more. December 2017 Webinar 12122017
 
Biopharmaceutical Products, GMP, Manufacturing Facilities for Biopharmaceuticals
Biopharmaceutical Products, GMP, Manufacturing Facilities for BiopharmaceuticalsBiopharmaceutical Products, GMP, Manufacturing Facilities for Biopharmaceuticals
Biopharmaceutical Products, GMP, Manufacturing Facilities for Biopharmaceuticals
 

Recently uploaded

+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
?#DUbAI#??##{{(☎️+971_581248768%)**%*]'#abortion pills for sale in dubai@
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Victor Rentea
 

Recently uploaded (20)

How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
 
ICT role in 21st century education and its challenges
ICT role in 21st century education and its challengesICT role in 21st century education and its challenges
ICT role in 21st century education and its challenges
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf
 
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
 
Cyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdfCyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdf
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
 
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 AmsterdamDEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
 
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdfRising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
Rising Above_ Dubai Floods and the Fortitude of Dubai International Airport.pdf
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
 
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
 

FDA Presentation on Biologics

  • 1. Overview of Biological Products FDA Basics Webinar June 17, 2013 Mantej (Nimi) Chhina, M.S., Ph.D. Health Science Policy Analyst Office of Medical Policy Center for Drug Evaluation and Research U.S. Food and Drug Administration
  • 2. Objectives • Biological products definition • What is a “biological product”? • Sources for biological products • Types of biological products • How are biological products different? • Questions from consumers and patients 2
  • 3. Definition of Biological Product Section 351, Public Health Service (PHS) Act – (1) The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings. 42 U.S.C. § 262(i) 3
  • 4. Examples of Biological Products • Biological products are used for a wide range of diseases and conditions, including serious and life-threatening conditions such as cancers and rheumatoid arthritis. Some examples of biological products and examples of their approved uses include: Botox: has both dermatologic and neurologic uses Herceptin: for a certain type of breast cancer Vaccines, for example: the Shingles vaccine and the flu vaccines Enbrel: for rheumatoid arthritis and psoriasis 4
  • 5. What is a Biological Product? 5 • Biological products, or biologics, are medical products. • Biological products could be made of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. • Like drugs, biological products are used to either:  treat or cure diseases and medical conditions,  prevent diseases, or  diagnose diseases • Biological products are made from a variety of natural sources.
  • 7. Types of Biological Products Blood Derivatives Proteins Whole Blood Human Tissues Xenotransplantation Products Vaccines (preventive and therapeutic) Allergenic ExtractsBlood Components Cellular & Gene Therapies 7
  • 8. How are Biological Products Different? 8 Small Molecule Drugs Biological Products Generally low molecular weight Generally high molecular weight Usually organic or chemical synthesis Made with/from live cells/organisms  inherent & contamination risk Fewer critical process steps Many critical process steps Well-characterized Less easily characterized Known structure Structure may or may not be completely defined or known Homogeneous drug substance Heterogeneous mixtures  May include variants Usually not immunogenic Often Immunogenic
  • 9. Aspirin 180 Da Monoclonal Antibody ~150,000 Da 9 Size and Complexity of Proteins
  • 10. Example of a Biotechnology Process Harvest Protein mixture Concentration Formulation Filling Fermentor Columns Purify Protein Live cells Biological Drug Substance Biological Drug Product 10
  • 11. Examples of Challenges for Biological Products • Must be processed under tightly controlled conditions/controls throughout production to – consistently produce a safe, pure, and potent product, and – preclude the introduction of environmental contamination • Biological products may be susceptible to extreme temperatures and light • typically need refrigeration but may need frozen storage or preservatives • shelf life may be limited 11
  • 12. Bringing a biological product to the US market • A manufacturer who seeks to market a biological product must submit a biologics license application (BLA), which includes: – Manufacturing information to demonstrate the company can properly and consistently manufacture the biological product – Data and information regarding the biological product (e.g., studies in animals and humans) – The company’s proposed labeling for the biological product. The labeling provides necessary information about the biological product, including uses for which it has been shown to be effective, possible risks, and how to use it. • The biological product is licensed and can be marketed in the United States only if – FDA determines that the data shows the biological product is safe and effective for its proposed use, and – the biological product can be manufactured in a way that ensures a quality product. 12
  • 13. Summary • Biological Products: diverse, complex products for the treatment, diagnosis and prevention of a broad range of common and rare diseases • Complex processes for manufacturing, product testing, and for evaluation of safety and efficacy • In contrast to most drugs that are chemically synthesized and have a known structure, most biological products are complex mixtures that are not as easily identified or characterized. • Healthcare professionals and consumers can be assured that FDA will require licensed biological products to meet the Agency’s exacting standards of safety and effectiveness. 13
  • 15. Remember to tune in for webinar on: Biosimilar Biological Products Monday, August 19, 2013 1:00 PM U.S. Eastern Time Zone 15